Hemostasis

FDA Approves Medafor's Technology for Control of Bleeding

Published in Blood Weekly, February 7th, 2002

Medafor, Inc., has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to market its technology as a topical hemostat for the local management of bleeding wounds.

TraumaDEX has been cleared for use by doctors and medical services personnel for temporary control of severe bleeding in a variety of trauma and postsurgical wounds. Bleed-X has been approved for over-the-counter use for cuts, lacerations and abrasions. Both are based on Medafor's Hemadex technology - a biopolymeric, microporous powder which produces rapid hemostasis in areas of profuse bleeding.

"Hemadex offers medical professionals unprecedented safety, ease...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry